Stockwinners Market Radar for September 03, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EDT Tidewater names Quintin Kneen as CEO - Tidewater announced that the board has appointed Quintin Kneen as CEO, and director of Tidewater, effective immediately. John T. Rynd is retiring as President, CEO, and director of Tidewater. Mr. Kneen, who has served as Executive Vice President and CFO of Tidewater since Tidewater's November 2018 business combination with GulfMark Offshore, Inc.

20:01 EDT Telaria to partner with Philippines' ABS-CBN Corporation - Telaria announced a partnership with ABS-CBN Corporation, the largest media and entertainment group in the Philippines. ABS-CBN will use Telaria's Video Management Platform to manage and monetize their OTT video inventory across all screens. Over 13 million viewers watch video content through ABS-CBN's OTT platform iWant which includes programming such as local news, reality TV, variety shows, and movies.

18:50 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Coupa Software (COUP) up 9.9%... Ferroglobe (GSM) up 4.0%. ALSO HIGHER: Puma Biotechnology (PBYI) up 10.3% after getting FDA orphan drug designation for Nerlynx... Box (BOX) up 6.7% after disclosing 7.5% activist stake from Starboard... Lumber Liquidators (LL) up 4.2% after speculation that its founder seeks talks about possible Cabinets to Go combination. DOWN AFTER EARNINGS: Safe Bulkers (SB) down 10.3%... Tyson Foods (TSN) down 6.0% after cutting FY19 guidance... HealthEquity (HQY) down 3.8%... eGain Corp (EGAN) down 1.5%. ALSO LOWER: Superior Industries (SUP) down 17.3% after suspending dividend payout... Aridis Pharma (ARDS) down 5.5% after mixed shelf offering... Redwood Trust (RWT) down 3.1% after equity offering... Okta (OKTA) down 2.1% after convertible note offering. Movers as of 18:30ET.

18:31 EDT Hub Group names Michele McDermott as Chief Human Resources Officer - Hub Group has appointed Michele McDermott as its first Chief Human Resources Officer. McDermott, who joined the company on August 19, reports to Chairman and CEO David Yeager and is based at Hub Group's Oak Brook, Ill., headquarters.

18:20 EDT Denny's CFO sells 10K shares of common stock - In a regulatory filing, Denny's disclosed that its CFO Mark Wolfinger sold 10K share of common stock on August 30th. The total transaction size was $235.7K.

18:10 EDT CF Industries CFO sells 95.2K shares of common stock - In a regulatory filing, CF Industries disclosed that its CFO Dennis Kelleher sold 95.2K share of common stock on August 29th-30th. The total transaction size was $4.6M.

18:00 EDT SPDR Gold Shares holdings rise to 890.04MT from 878.31MT - This is the highest level of holdings since November of 2016.

17:55 EDT Tyson Foods down 6% after lowering FY19 guidance - Shares of Tyson Foods are down 6% in the after-hours to $87.65 after the company lowered its FY 19 guidance, stating it was "experiencing short-term challenges that are negatively affecting Q4 earnings."

17:46 EDT Encore Wire CFO Frank Bilban to retire - Encore Wire Corporation announced that the company's VP and CFO, Frank Bilban, will retire in May of 2020. His successor, Bret Eckert was hired following an intensive search process.

17:43 EDT Leidos awarded $445.36M Air Force information technology services contract - Leidos has been awarded a $445.36M indefinite-delivery/indefinite-quantity contract for Air Force National Capital Region information technology services. This contract provides a full range of classified and unclassified information technology services in the National Capital Region. Work will be performed in the National Capital Region to include Joint Base Andrews, Joint Base Anacostia-Bolling and the Pentagon, and is expected to be complete by September 2, 2024. This award is the result of a competitive acquisition and three offers were received. FY19 operations and maintenance funds in the amount of $7.52M are being obligated at the time of award. The Air Force is the contracting activity.

17:32 EDT Facebook announces update to face recognition, helping users protect identity - Srinivas Narayanan, Applied Research Lead, Facebook AI said in a company blog posting: "Facebook has always given you control over whether we use face recognition technology to recognize you in photos. This setting was previously called tag suggestions because Facebook only used face recognition technology to automatically suggest tags of your friends in photos. In December 2017, we introduced a new setting for some people called face recognition. Our face recognition setting lets you manage not only whether Facebook uses face recognition technology on photos of you in order to suggest tags; it provides an easy on or off switch for a broader set of uses of face recognition, such as helping you protect your identity on Facebook...Starting today, people who newly join Facebook or who previously had the tag suggestions setting will have the face recognition setting and will receive information about how it works. The tag suggestions setting, which only controls whether we can suggest that your friends tag you in photos or videos using face recognition will no longer be available...hese changes will be effective globally starting today." Reference Link

17:13 EDT Elastic launches Elasticsearch service on Microsoft Azure - Elastic (ESTC) announced the launch of Elasticsearch Service on Microsoft's (MSFT) Azure for its managed service users who want more cloud provider options. Organizations that have standardized on Azure will now be able to enjoy the convenience of a fully managed Elasticsearch service, from the creators of Elasticsearch, on their preferred cloud platform.

17:02 EDT AptarGroup to partner with PureCycle on UPRP launch - AptarGroup announced that it has partnered with PureCycle Technologies, to prepare for the introduction of PureCycle's Ultra-Pure Recycled Polypropylene, or UPRP, into dispensing applications. PureCycle's ground-breaking, patented recycling process, developed and licensed by Procter & Gamble, separates color, odor and any other contaminants from plastic waste feedstock to transform it into UPRP resin with virgin-like properties. This process fully closes the loop in the reuse of recycled plastics while making recycled plastics more accessible at scale to companies desiring to use a sustainable, recycled resin. Over the next three years, Aptar will collaborate with and provide critical feedback to PureCycle regarding the transformation process of its UPRP. In addition to providing detailed feedback into how the resin performs during the transformation process, Aptar will play a role in helping PureCycle prepare for the food grade requirements in Europe.

16:48 EDT First Merchants announces 3M shares stock buyback - In a regulatory filing, First Merchants disclosed that on September 3, 2019, its board approved a stock repurchase program of up to 3M shares of the company's outstanding common stock provided that the total aggregate investment in shares repurchased under the program may not exceed $75M. On a share basis, the amount of common stock subject to the repurchase program represents approximately 5% of the company's outstanding shares.

16:39 EDT Red Lion Hotels enters pacts to sell hotels in Atlanta, Salt Lake City and D.C. - RLH announced that it has entered into non-binding sale agreements for its Red Lion Hotel Atlanta Airport, Hotel RL Washington D.C. and Hotel RL in Salt Lake City for an aggregate $64 million in gross proceeds. The transactions, which are subject to due diligence, financing contingencies and customary closing conditions, are expected to close by year-end. The sales are part of the Company's ongoing hotel asset disposition program.Each of these properties are held in joint ventures, of which the Company owns 55%. Net proceeds to the Company will be used to repay property level and corporate level debt. The Red Lion Hotel Atlanta will not be retaining the Red Lion flag. It is anticipated that the Hotel RL Washington D.C. and the Hotel RL Salt Lake City will retain their Red Lion flag during a transition period, to be determined, as the new property owners pursue a change in use. In addition to these three agreements, the Company is continuing its process to secure the sale of the Red Lion Hotel Anaheim. Greg Mount, Chief Executive Officer commented on the transactions, "We're pleased to announce the impending sale of three of our joint venture properties, including Salt Lake City which is not currently being formally marketed. These transactions are a continuation of our real estate marketing and disposition program as we focus on our franchise and branding strategy. We are encouraged by the renewed interest in our remaining owned hotels and will continue to work to successfully close on those assets in a manner that maximizes their value." The Company is increasing its previously communicated expectation for net sales proceeds to $35 to $45 million from $30 to $40 million. The net proceeds range reflects RLH's portion of the funds received upon completion of the sales for all of its owned hotels. While the Company is diligently pursuing the sales of its owned hotel assets, it can make no guarantees that the transactions will close.

16:36 EDT Stifel Financial completes acquisition of B&F Capital Markets - Stifel Financial Corp. announced that it has completed the acquisition of B&F Capital Markets, which provides regional and community banks with extensive interest rate swap capabilities.

16:33 EDT Stealth Biotherapeutics appoints Robert Weiskopf as CFO - Stealth BioTherapeutics announced the appointment of Robert Weiskopf as CFO. As CFO, Weiskopf will oversee a disciplined financial planning and growth strategy as Stealth prepares for the potential launch of elamipretide and advances its pipeline programs. Pivotal data is expected for the Company's lead product candidate, elamipretide, in primary mitochondrial myopathy in early 2020 and newly announced product candidate, SBT-272, is poised to enter the clinic by year-end 2019. Weiskopf brings more than 25 years of financial experience to Stealth, including a strong background in public biotech company operations and reporting from his 12-year tenure at ArQule, where he most recently served as CFO and Treasurer from 2015 to 2019.

16:33 EDT Air Lease delivers new Airbus A330-900neo aircraft to Hi Fly - Air Lease (AL) announced the delivery of one new Airbus A330-900neo aircraft on long-term lease to Portugal's Hi Fly. Featuring Rolls-Royce Trent 7000 engines, this A330-900neo delivered from ALC's order book with Airbus (EADSY).

16:31 EDT Silvercorp Metals reports increased reserves, resources at GC Mine - Silvercorp Metals reported the results of an updated National Instrument 43-101 Technical Report with an effective date of June 30, prepared by AMC Mining Consultants on the Gaocheng silver-zinc-lead property, also called the GC Mine, in Guangdong Province, People's Republic of China. From the start of operations at the GC Mine in 2014 through to December 31, 2018, 1.25M tonnes have been mined at average head grades of 96 g/t silver, 1.5% lead and 2.7% zinc. Despite mine production depletion, there has been a 7% increase in tonnes of Proven and Probable Reserves compared to the Mineral Reserve estimate in the previous Technical Report. Based on Proven and Probable Reserves only, the GC Mine has a projected life of mine of 12 years through to 2031, at an average annual production rate of approximately 300,000 tonnes, and with average silver equivalent grades of approximately 334 g/t for the first six years and then 271 g/t for the remainder of the mine life. The GC Mine also has the potential to extend the LOM beyond 2031, via conversion of existing Mineral Resources to Mineral Reserves, and further exploration and development. Measured and Indicated Mineral Resource tonnes increased by 42%, which is due to an increase in the number of veins and conversion of Inferred material to a higher classification level. Inferred tonnes have decreased by 3%. The results of the underground drilling program at the GC Mine show that vein structures are still open at depth.

16:23 EDT Puma Biotechnology's Nerlynx gets FDA orphan drug designation - Puma Biotechnology announced that the FDA has granted Orphan Drug Designation to NERLYNX, or neratinib, for the treatment of breast cancer patients with brain metastases. CEO Alan Auerbach says: "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to developing treatments for patients with HER2-positive breast cancer."

16:22 EDT Superior Industries suspends quarterly dividend payout - Superior Industries announced that its board determined to suspend the quarterly common dividend. "While Superior had substantial availability under committed credit lines and cash totaling $264M at the end of the second quarter of 2019, we believe that focusing our capital allocation strategy on reinvestment in the business and reducing our net debt position will deliver the most long-term value to our shareholders. As a result, our Board of Directors determined to suspend our common dividend, allowing Superior to reallocate approximately $11 million of cash on an annualized basis to support this strategy," commented Majdi Abulaban, President and Chief Executive Officer of Superior.

16:19 EDT Melinta Therapeutics appoints Jennifer Sanfilippo interim CEO - Melinta Therapeutics announced that Jennifer Sanfilippo has been named interim CEO and director, effective August 28. Prior to this appointment, Sanfilippo served as senior VP and general counsel of Melinta.

16:18 EDT SP Plus Corp. appoints Ritu Vig as Chief Legal Officer - SP Plus Corporation announced the appointment of Ritu Vig as Chief Legal Officer and Secretary. Vig joined SP Plus as senior VP, Deputy General Counsel in 2018.

16:18 EDT Camping World evaluating shift or closing of up to 37 retail locations - Camping World announced that management and its board of directors approved a plan to strategically shift away from locations where the company does not have the ability or where it is not feasible to sell and/or service RVs. Currently, the company operates 165 locations that sell and/or service RVs, with over 30 RV dealership locations opened or acquired since January 1, 2018. In addition, the company operates 37 locations which do not sell and/or service RV's but sell its assortment of outdoor lifestyle products. At certain locations that do not sell and/or service RVs, the company is in the process of attempting to acquire and/or obtain the developmental consents, approvals and permits necessary for the sale and/or service of RV's. The company is in the early stages of evaluating the impact of the Plan and has had preliminary discussions regarding the sale, repurposing, relocating or closing of certain locations, with the current expectation of either selling, repurposing, relocating or closing approximately 27 to 37 locations. The actual number of stores the company sells, repurposes, relocates, or closes may change. As part of the Plan, the company is also evaluating the impact on the company's supporting infrastructure and operations and expects the majority of the activities contemplated under the Plan to be completed by year-end.

16:14 EDT Realty Income to buy 454 single-tenant retail properties from CMFT for $1.25B - Realty Income announced that it has signed a definitive agreement to acquire 454 single-tenant retail properties from CIM Real Estate Finance Trust, or CMFT, a non-listed REIT which is sponsored by an affiliate of CIM Group, for approximately $1.25B in cash. The transaction is expected to close in various tranches with the acquisition of most of the properties in the portfolio expected to close in 2019, subject to customary closing conditions. The transaction is expected to be executed at an approximate 7% cash cap rate, resulting in an investment spread relative to its first-year weighted average cost of capital well above the company's historical average. The portfolio carries a weighted average remaining lease term of 9.7 years and generates 58% of total rental revenue from investment-grade rated companies or their subsidiaries. The portfolio being acquired from CMFT consists of 454 properties with approximately 5.1M leasable square feet. The properties in the portfolio are currently leased to 59 different tenants across 20 industries, with Texas and California. Based on the tenant and industry concentrations for this portfolio, Realty Income does not expect the acquisition, once completed, to have a meaningful impact on its existing tenant and industry concentrations.

16:11 EDT Scientific Games selected for the Turkish National Lottery - Scientific Games announces that it has been chosen by the winning joint venture for the Turkish National Lottery to exclusively supply lottery instant games, its latest generation WAVE retail technology and supporting systems for 10 years in the nation of more than 80M. Additionally, Scientific Games and its Turkish partner, ans Dijital, were recently selected to exclusively deliver and operate sports betting and managed trading in Turkey, among the world's largest state-sponsored sports betting markets. For the Turkey National Lottery, Scientific Games will provide up to 15,000 of the Company's latest generation WAVE retailer terminals, a secure instant ticket validation system and its world-leading instant games. The National Lottery launch in Turkey is planned for 2020.

16:08 EDT Castle Biosciences reports Q2 EPS ($1.05), consensus ($1.36) - Reports Q2 revenue $10.7M, consensus $7.48M. As of June 30, 2019, our cash balance was $17.5 million and the outstanding principal balance on our bank term loan was $26.7 million.

16:07 EDT Frequency Electronics delivers fourth in a series od WAAS - Frequency Electronics announced that it has delivered its fourth in a series of Wide Area Augmentation System, WAAS, Timing and Frequency Conversion systems to Northrop Grumman Innovation Systems, Inc., subcontractors on the 7th Generation geostationary earth orbit satellite, GEO 7,task order. Consisting of dual redundant C-to-L band down converters and triple redundant ultra-stable quartz oscillators, the system enables the delivery of precision navigation information to aircraft and is scheduled to be launched in 2020 aboard the Intelsat Galaxy 30 satellite. WAAS is an air navigation aid developed by the Federal Aviation Administration to augment the Global Positioning System, GPS, with the goal of improving its accuracy, integrity, and availability. WAAS enables precision instrument approach capability for aircraft in all weather, critical for safe and efficient operations in the US airspace system.

16:07 EDT Stereotaxis announces uplisting to NYSE American - Stereotaxis announced that its common stock has been approved for listing on the NYSE American. The company's common stock will begin trading on the NYSE American exchange under its current symbol, "STXS," at the open of trading on September 6. The company's common stock will continue to trade on the OTCQX until the close of the market on September 5.

16:05 EDT Nobilis Health trading halted, news pending

16:03 EDT MGM Resorts issues statement on future of Village property - MGM Resorts released the following statement: "We know that for many, the Village property will forever be linked to the tragic loss of life that took place there on October 1st. We will never forget the victims, and all of those impacted by that evening. As the second anniversary nears, we remain committed to being part of the community effort to continue healing and moving forward. In this spirit, MGM Resorts plans to build a community and athletic center on the north end of the property, which will be home to sporting events and community gatherings. We hope one day it will host high school basketball tournaments, indoor soccer for kids and provide a place for the Aces to practice and engage with the community to inspire the next generation of female athletes. It was important to us that the long-term use of the property include the community in some way. We also plan to create a space on the property to remember the victims of the tragedy. In the near term, while these plans are underway, the property will revert back from festival grounds to a parking area and will serve as parking during games and concerts taking place at Allegiant Stadium. Over the coming weeks and months, there will be construction activity near the property to ensure the safety of pedestrians crossing the street toward the stadium. We will share plans for the community and athletic center as they advance. We will also support the future community effort around a permanent, public memorial when that process begins."

15:10 EDT Eldorado Gold announces receipt of Skouries and Olympias installation permits - Eldorado Gold confirms receipt of electromechanical installation permits for its Skouries project and an installation permit for its Olympias mine from the Greek Ministry of Energy and Environment. At Skouries, Eldorado said it intends to carry out certain construction activities that were suspended in 2017, including building the mill enclosure once permitted, to protect the plant assets. Capital expenditure for asset protection works is estimated to be approximately $5M. At Olympias, the permit allows for installation of an upgraded electrical substation and construction of support facilities, which will be considered as part of Eldorado's annual planning process. Eldorado said it is working with the Greek government to achieve the necessary conditions required to restart full construction at the Skouries Project. "The Ministry and the Company are collaborating on a mutually acceptable path forward to build safe, modern, world-class operations in Greece, including approval to implement dry stack tailings at Skouries. This best-available technology would reduce the project's environmental footprint by approximately 40% and decrease the site's water consumption," the company said. George Burns, President and CEO of Eldorado Gold added, "We are greatly encouraged with the engagement we've had to date with the Greek State and look forward to working constructively with the relevant Ministries. We believe the Skouries project offers significant value for our investors and benefits to the local communities and the Greek economy, while adhering to the highest environmental standards."

14:49 EDT Hydrogenics announces court approval for proposed transaction with Cummins - Hydrogenics (HYGS) announced earlier that it has obtained a final order from the Ontario Superior Court of Justice approving the previously-announced plan of arrangement pursuant to which Atlantis AcquisitionCo Canada Corporation, a subsidiary of Cummins (CMI), will, among other things, acquire all of the outstanding common shares of the company other than the shares owned by The Hydrogen Company, a wholly owned subsidiary of L'Air Liquide S.A., for $15.00 in cash per share. The Hydrogen Company has agreed to contribute its shares for common shares of the purchaser on a one for one basis, pursuant to the transaction in lieu of receiving the cash consideration from the purchaser for its shares. Completion of the transaction remains subject to the satisfaction of certain customary closing conditions. Subject to the satisfaction or waiver of all of the conditions to the transaction, the transaction is expected to be completed on or about September 9.

14:07 EDT Google releases final version of Android 10 with more security - In an earlier blog posting, Google said: "Android 10 is officially available, and it delivers a wealth of helpful features to employees and more security and control for IT. This release not only marks the 10th version of Android, but also highlights our strong, sustained investment in enterprise features going back to Android 5.0 with the introduction of the work profile and many other management tools. We're providing employees more flexibility and privacy when using a corporate-owned device. Organizations can now provision company-owned devices into work profile mode using zero-touch enrollment or other enrollment methods, so employees can enjoy even more privacy when using their work device for personal reasons and IT admins have one consistent way of managing across company-owned and BYOD devices." Reference Link

13:32 EDT Walmart to discontinue handgun sales in Alaska

13:31 EDT Walmart CEO says sending letters calling for action on common sense measures - Walmart CEO Doug McMillon says, "We do not sell military-style rifles, and we believe the reauthorization of the Assault Weapons ban should be debated to determine its effectiveness. We must also do more, as a country, to understand the root causes that lead to this type of violent behavior. Today, I'm sending letters to the White House and the Congressional leadership that call for action on these common sense measures. As we've seen before, these horrific events occur and then the spotlight fades. We should not allow that to happen. Congress and the administration should act. Given our decades of experience selling firearms, we are also offering to serve as a resource in the national debate on responsible gun sales."

13:17 EDT C-Band Alliance responds to Eutelsat decision to withdraw from alliance - C-Band Alliance members Intelsat (I), SES and Telesat stated that they are "fully committed to the market-based approach for clearing C-band spectrum in the U.S." following Eutelsat's (EUTLF) decision to withdraw from the alliance. The group issued the following response: "The C-Band Alliance notes the statement of Eutelsat issued today to withdraw from the Alliance. The CBA remains committed to delivering its expeditious, market-based proposal and the departure of Eutelsat does not impact the CBA's ability to do so. The remaining members of the CBA, which represent approximately 95% of the affected revenues of the U.S. C-band market, are aligned and committed to the process of engaging with the FCC on the proposal of rapidly clearing C-band spectrum to support the deployment of 5G services in the U.S." In afternoon trading, Intelsat shares are down $1.50, or 7.25%, to $19.18.

13:01 EDT Sally Beauty appoints Pamela Kohn Chief Merchandising Officer - Sally Beauty Holdings announced Pamela Kohn has been appointed as senior VP, Chief Merchandising Officer, with an expected start date of October 1. Kohn most recently served as executive VP, Chief Merchandising and Marketing Officer for the Family Dollar Division of Dollar Tree. Prior to that, she held the same role for The Fresh Market.

12:00 EDT California Resources falls -13.1% - California Resources is down -13.1%, or -$1.28 to $8.51.

12:00 EDT Navios Maritime falls -16.6% - Navios Maritime is down -16.6%, or -$1.05 to $5.27.

12:00 EDT Emergent BioSolutions rises 13.8% - Emergent BioSolutions is up 13.8%, or $6.04 to $49.84.

11:02 EDT AT&T appoints John Stankey as COO - AT&T announced that John Stankey has been appointed president and COO of AT&T, effective October 1, a new position reporting to Randall Stephenson, AT&T chairman and CEO. Stankey will also continue serving as CEO of WarnerMedia. The company named AT&T executive Jeff McElfresh CEO of AT&T Communications effective October 1, replacing John Donovan, who earlier announced his retirement. Reporting to Stankey in his expanded role will be: McElfresh; his current WarnerMedia executive team; and Brian Lesser, CEO of Xandr.

10:46 EDT Vitamin Shoppe launches Only Me personalized vitamin subscription service - The Vitamin Shoppe announced the launch of Only Me, a personalized online assessment that delivers a custom assortment of vitamins and supplements to participating subscribers each month. Vitamin Shoppe said "The new subscription service from The Vitamin Shoppe provides customers with a unique wellness regimen tailored to their individual health and lifestyle needs, while offering trusted, high-quality products from The Vitamin Shoppe." It added, "Designed by medical experts, Only Me utilizes a detailed questionnaire about current health status and daily routines to curate a wellness plan for each individual. Once the assessment is complete, customers can expect a uniquely sourced daily regimen, providing them with vitamins and supplements essential to their foundational health. Each plan is individually tailored to also include support for brain, mood, energy, sleep, immunity, digestive, aging, gender and maternal need states." The personalized subscription service is priced starting at $20 per month, with individual plan prices based upon the total recommended products and dosages.

10:12 EDT Eastern Company sees Big 3 Precision transaction 'immediately accretive' - The company said, "The transaction is expected to be immediately accretive, excluding transaction expenses and purchase accounting adjustments, and accretive by at least 40c per share to EPS in Fiscal 2020."

10:00 EDT Navios Maritime falls -9.3% - Navios Maritime is down -9.3%, or -58c to $5.74.

10:00 EDT Borr Drilling falls -10.4% - Borr Drilling is down -10.4%, or -61c to $5.23.

10:00 EDT VelocityShares 3x Long Natural Gas ETN rises 10.2% - VelocityShares 3x Long Natural Gas ETN is up 10.2%, or $1.50 to $16.20.

09:56 EDT Penns Woods Bancorp board of directors approves 3-for-2 stock split - Penns Woods Bancorp CEO Richard Grafmyre has announced that the company's Board of Directors approved a 3 for 2 stock split on September 3, 2019. The split will increase shares outstanding by 50% or approximately 2,346,462 shares. Total outstanding shares after the split will total approximately 7,039,389. The split is payable September 30, 2019 to shareholders of record September 17, 2019. Cash will be paid in lieu of fractional shares.

09:47 EDT Borr Drilling falls -11.6% - Borr Drilling is down -11.6%, or -68c to $5.16.

09:47 EDT Britannia Bulk rises 9.8% - Britannia Bulk is up 9.8%, or 65c to $7.26.

09:47 EDT Banco Macro rises 7.4% - Banco Macro is up 7.4%, or $1.72 to $25.03.

09:26 EDT Monarch Casino says PCL lawsuit 'principally an effort to deflect attention' - Monarch Casino & Resort provided the following comment on disagreements with its general contractor in Black Hawk, PCL Construction Services, which have resulted in PCL filing a preemptory lawsuit on August 30, 2019 against Monarch and its Colorado subsidiaries. "Since engaging PCL as general contractor at Monarch Casino Black Hawk, we have worked tirelessly to move the construction project forward. While Monarch has been frustrated with PCL's numerous construction delays and cost increases, we have remained focused on the transformation of Monarch Casino Black Hawk. Monarch believes that PCL's lawsuit is principally an effort to deflect attention from their failures to deliver the completed project in a timely and cost appropriate manner. Unfortunately, we must now respond to PCL's lawsuit with our affirmative defenses as well as counterclaims against PCL which will detail their numerous contract and performance breaches. That said, we will continue to work with PCL to complete our new Monarch Casino Resort Spa Black Hawk. Given this lawsuit, the increasingly adversarial tone of communication from PCL, and our understanding of recent discussions regarding project delivery, we now believe that our expansion project - the new Monarch Casino Resort Spa Black Hawk - including the expanded casino, restaurants and certain public areas - should be fully open in the first quarter of 2020. The remaining remodeling of some areas of the existing casino is expected to be completed in the second quarter of 2020. Our disappointment with the ongoing construction delays at the expanded Monarch Casino Black Hawk is palpable. Importantly, other than a delay of the finished project, the customer experience should not be impacted at the property, now or in the future. Given the terrific guest response to the property's enhancements introduced to date, our entire team knows that the fully transformed Monarch Casino Resort Spa Black Hawk will be a game changer for this exciting and vibrant market. While PCL's performance has delayed our opening from our earlier announced dates, it will only increase the excitement of our team to deliver Black Hawk's best-in-class resort and hospitality destination for visitors from across the Denver metropolitan area."

09:22 EDT Consolidated-Tomoka acquires Alpine Valley Music Theatre for $7.5M - Consolidated-Tomoka Land announced the purchase of a 37,000-capacity amphitheater, which includes a 7,500-seat pavilion and extensive green space covering over 150 acres, located in East Troy, Wisconsin. The renowned Alpine Valley Music Theatre is central to several metropolitan areas including Chicago, Illinois, Milwaukee, Wisconsin, and Madison, Wisconsin, and attracts a wide-ranging audience for annual performances. The Alpine Property is under an absolute net lease with Live Nation Entertainment, Inc. with a remaining lease term of approximately 11 years which includes annual rental increases. The initial investment cap rate for the acquisition of the Alpine Property is near the high-end of the Company's 2019 guidance for income property acquisitions. The acquisition of the Alpine Property increases the Company's geographic footprint to sixteen states. Including this transaction, the Company's income property portfolio consists of 50 properties, of which 46 are single-tenant and four are multi-tenant properties. This acquisition was purchased using the Company's line of credit and is expected to be part of a 1031 like-kind exchange.

09:18 EDT Abeona Therapeutics announces strategic review - Abeona Therapeutics announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company's mission and maximizing stakeholder value. In response to interest, Abeona has initiated a process to explore a broad range of strategic alternatives, including, but not limited to the partnering of its various clinical and pre-clinical programs, or a sale or merger of the Company, in an effort to unlock the potential of those assets. "With four clinical stage programs, a broad pre-clinical pipeline, GMP manufacturing facilities, and a talented team, Abeona remains committed to advancing the promise of genetic medicine," said Joao Siffert, M.D., Chief Executive Officer. "Given our expertise in gene and cell therapy, we believe we are well positioned to explore a variety of opportunities, pursue strategic partnerships and alliances, improve our capital structure, and accelerate development of candidates towards commercialization."

09:15 EDT National Instruments and ETAS announce approval of joint venture - National Instruments and ETAS announced that the antitrust authorities have approved the creation of their joint venture. The new company, ETAS NI Systems GmbH & Co. KG, will be fully operational by January 1, 2020. The joint venture, headquartered in Stuttgart, Germany, plans to employ 50 people and scale for growth. NI and ETAS each own 50% of the new company. The joint venture, which was announced in March, will establish a deeper partnership between two innovators with decades of experience in the automotive test industry.

09:14 EDT Fly Intel: Pre-market Movers - HIGHER: The Medicines Co. (MDCO), up 10% after announcing that ORION-11, its first pivotal Phase 3 clinical study of inclisiran, met all primary and secondary efficacy endpoints... Ardelyx (ARDX), up 25% after announcing the AMPLIFY study met the primary endpoint and all key secondary endpoints, including demonstrating a statistically significant reduction in serum phosphorus levels for patients treated with tenapanor and phosphate binders compared to phosphate binders alone. UP AFTER EARNINGS: Conn's (CONN), up 14%... Tufin (TUFN), up 2%. LOWER: Boeing (BA), down 3% after The Wall Street Journal reported tension between Boeing and international air-safety authorities could delay the grounded 737 Max fleet from getting back into service. Reportedly, additional weeks of delay could significantly reduce the likelihood that the 737 Max is back in the air during the Christmas holidays... Aridis (ARDS), down 27% after its AR-105 trial did not meet its primary endpoint of demonstrating superiority in clinical cure rates on Day 21 compared to placebo... ProPetro (PUMP), down 6% after disclosing that Mark Howell informed the board of directors of the company of his intent to resign from his position as the general counsel and corporate secretary of the company, effective September 29.

09:11 EDT SailPoint appoints Matt Mills as Chief Revenue Officer - SailPoint Technologies Holdings announced the appointment of Matt Mills to Chief Revenue Officer, or CRO. In this role, Matt will lead SailPoint's global sales organization, driving the company's overall go-to-market strategy and execution. Matt brings over 30 years of experience to his role as SailPoint's Chief Revenue Officer. Matt spent over 20 years at Oracle as Senior Vice President North America Sales where he oversaw over 8,000 employees and was responsible for $4.5B in annual revenues. He also sat on the company's executive committee where he played an instrumental role in its strategic go-to-market shift to the cloud. More recently, Matt was the CEO of MapR Technologies until 2018 and is currently a board advisor and member to early-stage SaaS companies.

09:11 EDT Roche extends offer for Spark Therapeutics to October 1 - Roche (RHHBY) announced another extension of its $4.3B takeover bid for U.S.-based gene therapy company Spark Therapeutics (ONCE). The extension to October 1 was given to provide more time for regulatory reviews, the company said in a regulatory filing.

09:10 EDT Terreno Realty acquires property in Brooklyn for $80.5M - Terreno Realty acquired an industrial property located in Brooklyn, New York on August 29, 2019 for a purchase price of approximately $80.5M. The property consists of two industrial distribution buildings containing approximately 192,000 square feet on 6.0 acres in East Williamsburg. The property, at 134-154 Morgan Avenue, provides 31 dock-high and ten grade-level loading positions, parking for 45 cars and is 100% leased to eight tenants, all of which expire within four years. The estimated stabilized cap rate of the property is 4.0%.

09:07 EDT WEC Energy to acquire 80% interest in Thunderhead Wind Energy Center for $338M - WEC Energy Group announced that the company has agreed to acquire an 80% ownership interest in Thunderhead Wind Energy Center. The project is being developed in Antelope and Wheeler counties, Nebraska by Invenergy. Commercial operation is expected to begin by the end of 2020. The wind farm has a long-term offtake agreement with a Fortune 100 company for 100% of the energy produced. The Thunderhead site will consist of 108 wind turbines with a combined capacity of 300 megawatts. WEC Energy Group's investment will total $338M for the 80% ownership interest. Under the tax rules, the WEC Energy Group investment is expected to be eligible for 100% bonus depreciation and production tax credits. The transaction is subject to receiving all necessary regulatory approvals.

09:05 EDT Titan Medical granted patent related to the company's dual-view camera system - Titan Medical announces that it has been granted U.S. Patent No. 10,398,287, titled "Camera Positioning System, Method, and Apparatus for Capturing Images During a Medical Procedure." The patent is directed at aspects of the Company's innovative dual-view camera system for use in robotic surgery, including single-port robotic surgery. Additional patent applications directed at other aspects of the dual-view camera system remain pending. With this patent grant and the Company's latest patent filings, Titan now has 45 patents issued and 82 patent applications.

09:04 EDT Easterly Government Properties acquires 169,585-sf EPA regional HQ in Lenexa, KS - Easterly Government Properties announced that it has acquired a 169,585-square foot Environmental Protection Agency Regional Headquarters in Lenexa, Kansas. EPA - Lenexa is a single tenant GSA-leased office building which serves as the Region 7 headquarters for the EPA. Originally constructed in 2007, the two-level office building, which is situated on a 30.5-acre parcel of land, underwent a large-scale renovation-to-suit for the EPA in 2012 whereby the facility received U.S. Green Building Council's LEED Gold for New Construction certification in April 2014.

09:03 EDT Neovasc announces Neovasc Reducer added to ESC Practice Guidelines - Neovasc announced that its Neovasc Reducer for the treatment of patients suffering from refractory angina has been added to the European Society of Cardiology Practice Guidelines. The ESC now recommends that the Reducer might be considered for the treatment of patients with angina, refractory to medical and interventional therapies.

09:02 EDT ENGlobal receives $6M extension to contract award - ENGlobal reported it has received an extension valued at $6M to perform additional work on a project that was initiated and announced in October of last year. ENGlobal has been engaged to provide process analytical engineering and related support services to assist in the restart of an idled oil refinery and terminal into a fully functioning and environmentally compliant facility. The Company's awards to date on this restart project now total approximately $12M, and the extension is expected to be performed over the next six months. ENGlobal has been called upon to execute the first of its customer's multiple phase plan - featuring a thorough upgrade to the analytical and instrumentation equipment at the refinery and terminal. Specifically, this work requires that ENGlobal provide home office engineering, detailed design, material procurement and an on-site installation and commissioning staff. The additional phases are expected to require similar services that will be performed in different areas of the facility until the refinery and terminal is successfully restarted and fully functional. "We sincerely thank our valued customer for their confidence in our abilities and performance to date, as demonstrated by this extension of our services," said Chairman and CEO William A. Coskey, P.E. "We are committed to providing excellent resources and successfully meeting the time critical schedule for restarting this facility. ENGlobal continues to seek out internal growth - to scale up our business through a focus on executing larger scopes of work. We are making progress on our modular systems strategy and have been successful in identifying and bidding numerous larger opportunities. In support of this point, we overall now have $275M of proposals outstanding that are awaiting customer decisions."

08:59 EDT Francesca's appoints Richard Emmett as chair, begins to explore board expansion - Francesca's Holdings announced that its Board of Directors appointed Richard Emmett to replace Richard Kunes as Chair, effective November 1, 2019. Mr. Kunes will continue to serve on the Board of Directors until January 31, 2020 as previously announced, and will continue to serve as chair of the Board until November 1, 2019. Emmett joined the Company's Board in December 2009. The Company also announced that its Board of Directors has begun exploring expansion of the Board, using a search process commenced by its Nominating and Governance Committee in accordance with that Committee's policies and criteria. The possible expansion is subject to identifying additional qualified and experienced candidates.

08:57 EDT Bayer hires Marianne De Backer as head of pharmaceuticals business development - Bayer (BAYRY) announced Marianne De Backer PhD as the new Head of Business Development & Licensing of its Pharmaceuticals Division. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company's Pharmaceuticals Division and join the Pharmaceuticals Executive Committee with immediate effect. De Backer will be based in Berkeley, CA, USA and lead Bayer's external pharmaceutical growth strategy and activities globally in all key areas of pharmaceutical innovation and alliance management. De Backer joins Bayer from Johnson & Johnson (JNJ) where she spearheaded Business Development activities across different therapeutic areas and geographies. She most recently held the position of Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and led Infectious Diseases & Vaccines Business Development including transactions, acquisitions, scientific licensing and alliance management.

08:54 EDT AgEagle actively pursuing opportunities in Drone Logistics, Transportation - AgEagle Aerial Systems has begun to actively pursue expansion opportunities within the emerging Drone Logistics and Transportation market - a market forecasted to grow to $29B in the next eight years. Barrett Mooney, CEO of AgEagle, stated, "Over the past year, there has been a surge of prominent companies, including Alphabet, FedEx, Intel, Qualcomm, Amazon, Target, Walmart, Alibaba, UPS, 7-Eleven, Uber and many others, actively developing commercial drone-delivery service initiatives as part of their long-term strategic plans. These companies intend to leverage the latest in unmanned aerial vehicle technologies to deliver food, consumer products, medicines and other types of lightweight freight direct to consumers and businesses in the fastest, most cost efficient and environmentally responsible manner possible - a practical alternative to costly auto transport. We have received our first purchase orders to manufacture and assemble UAVs designed to meet the critical specifications for drones that are meant to carry goods in urban and suburban areas. We look forward to providing greater detail in the near future on AgEagle's plans to address the needs of this highly specialized new market and the specific role we expect to play in its ongoing development. AgEagle's proven expertise in manufacturing rugged, reliable and professional grade UAVs makes our company a logical partner for designing, manufacturing, and testing drone platforms in the fast-growing delivery market. Not only does this represent an exciting new revenue channel, but it could yield material growth opportunities for us in the greater drone logistics and transportation market in the years to come."

08:48 EDT Alimera Sciences launches ILUVIEN in Germany - Alimera Sciences announces that it will immediately commence the launch of ILUVIEN in Germany for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. Following the European Union's Mutual Recognition Procedure in March 2019, Germany is the second country in Europe in which ILUVIEN is now commercially available to be prescribed to patients suffering from NIPU, a disease with no sustained treatment options. In June 2019, Alimera announced a positive recommendation by the National Institute for Health and Care Excellence, facilitating launch of the NIPU indication in the United Kingdom. Launch of the NIPU indication follows the establishment of national pricing and receipt of the required regulatory approval by the Federal Institute for Drugs and Medical Devices, the medical regulatory authority in Germany. Germany is Alimera's largest direct market in Europe based on current sales for ILUVIEN's diabetic macular edema indication, and it is estimated that the number of patients diagnosed with NIPU is approximately 15-20% of the DME patient population.

08:47 EDT SPX Corporation apppoints Meenal Sethna to board of directors - SPX Corporation (SPXC) announced Meenal Sethna as a new independent member of the Board of Directors of SPX Corporation, effective October 1, 2019. In addition to Board membership, Ms. Sethna has been appointed to serve on the Board's Audit Committee. Sethna currently serves as EVP and CFO of Littelfuse (LFUS).

08:44 EDT Luckin Coffee announces launch of Luckin Tea as independent brand - Luckin Coffee announced the launch of Luckin Tea as an independent brand and its brand ambassador Zhan XIAO, as well as a pilot program for its pioneering Retail Partnership model to recruit partners nationwide. The Company expects both Luckin Tea and Luckin Coffee stores to function in highly complementary roles. In terms of product category, Luckin Tea stores will also sell a standard range of classic freshly-brewed coffee, with a broader enriched assortment of freshly-brewed tea drinks. In addition, Luckin Tea stores will focus more on "leisurely" consumption moments, targeting locations in shopping malls and other lifestyle-centric commercial areas, while Luckin Coffee stores will continue to expand its presence primarily in office locations. Strategically, Luckin Tea stores will initially be rolled out in Tier 2 through Tier 4 cities, whereas Luckin Coffee will focus on Tier 1 and Tier 2 cities. Luckin Tea will consistently take Luckin Coffee's core value of "quality first", providing high quality, high convenience, and high affordability freshly-brewed tea drinks to consumers. Luckin Coffee also announced its pilot Retail Partnership model to support the expansion of Luckin Tea. Different from traditional franchise model, the Company's Retail Partnership model has multiple advantages for its partners, including attractive terms with no upfront partnership fees, reduced operational risk, the ability to leverage the Company's pervasive brand recognition, premium products and extensive supply chain, as well as access to the Company's disruptive technology-driven new retail model. Through the Company's innovative Retail Partnership model and digitalized operation platform, partners will not only be able to control their service quality effectively but also mitigate investment risk while increasing profitability at their stores.

08:42 EDT PhaseBio announces data from evaluation of pharmacodynamics of PB2452 - PhaseBio Pharmaceuticals announced that data from an evaluation of the pharmacodynamics of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, were presented by Lisa K. Jennings, Ph.D., Professor of Medicine, University of Tennessee Health Science Center, at ESC Congress 2019 in Paris on September 1. The first-in-human, randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluated the safety, efficacy and pharmacokinetics of intravenous PB2452 as a ticagrelor reversal agent in 64 healthy volunteers aged 18 to 50 years. Platelet function was assessed using light transmission aggregometry, VerifyNow PRUTest and vasodilator stimulated phosphoprotein assays. VerifyNow PRUTest is considered to be the gold standard for point-of-care assessments of platelet function. The data demonstrated that complete reversal by all measurements occurred within 15 minutes of administration and was sustained for over 20 hours. PhaseBio has continued to use the same three assays to demonstrate the efficacy of PB2452 in a Phase 2a trial and has continued to see a high degree of correlation among the assays in both trials.

08:39 EDT Akouos announces two leadership appointments - Akouos announced two key leadership appointments. Gregory Robinson, has joined as Chief Scientific Officer, and co-founder Michael McKenna, expands his role to full-time Chief Medical Officer. Robinson brings more than 20 years of scientific leadership experience. Most recently, he served as the chief scientific officer at Nightstar Therapeutics (NITE), an AAV gene therapy company focused on inherited retinal diseases. Greg was a key member of the leadership team that led Nightstar to its $800M Biogen (BIIB)acquisition earlier this year. Prior to Nightstar, Robinson was the chief scientific officer of Agilis Biotherapeutics, where he was responsible for advancing research programs focused on AAV-based gene therapy candidates for the treatment of rare central nervous system disorders. Previously, he held leadership roles at Shire Plc., where he led discovery research. He has also held positions at Eyetech Pharmaceuticals, Pharmacia Ophthalmology and Hybridon. He has co-authored more than 40 peer-reviewed publications

08:37 EDT National General to divest Euro Accident Health and Care Insurance - National General Holdings announced that it has entered into an agreement to sell its Euro Accident Health and Care Insurance Sweden operation to an investor group arranged by Impilo AB, a Swedish investment company focused on Nordic healthcare investments. Euro Accident Sweden provides health insurance, predominantly personal medical insurance or PMI which is an enhanced medical policy that supplements a national health care plan provided to large group and individuals. The estimated sale price for this transaction is $138M, which would result in an estimated pre-tax gain on sale of $3M, which is net of a negative realized FX translation impact of $22M. Since this transaction is based in Swedish Krona and will reflect certain closing adjustments, the final price and gain on sale will vary accordingly. The transaction is expected to close in late 2019 or early 2020, subject to customary closing conditions and regulatory approvals. Euro Accident Sweden net earned premium was $50M for the first six months of 2019 and $111M for full year 2018. Euro Accident Sweden's contribution to National General's pre-tax earnings was a loss of $3M for the first six months of 2019 and a pre-tax gain of $3M for full year 2018.

08:36 EDT Emmaus Life Sciences announces patent allowance from European Patent Office - Emmaus Life Sciences announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office. The allowance of this application follows the issuance of corresponding patents in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia. Patent applications are currently pending in various jurisdictions around the world, including Brazil and India. The allowed European application reports a significant reduction in the number of intestinal diverticula, the primary indicator of diverticulosis, through the therapeutic application of -pharmaceutical-grade L-glutamine, or PGLG. There are no commercial therapies that claim an ability to reduce intestinal diverticula at the present time. The covered invention is directed to methods and/or compositions for the treatment of diverticulosis. It is more specifically directed to compositions including PGLG or uses of such compositions in the treatment of diverticulosis. Diverticulosis refers to a condition where pouches form along the colon wall. Over time, some people get an infection in the pouches.

08:35 EDT Ultragenyx, GeneTx announce orphan drug, rare pediatric designations for GTX-102 - GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation and Rare Pediatric Disease Designation to GTX-102 for the treatment of Angelman Syndrome, a serious, debilitating rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide. GTX-102 is currently in late preclinical development, and an investigational new drug application is expected to be filed with the FDA in the first half of 2020. In August 2019, Ultragenyx and GeneTx announced a partnership to develop GTX-102 with Ultragenyx receiving an exclusive option to acquire GeneTx.

08:33 EDT ShockWave receives FDA breakthrough device designation for Coronary IVL System - Shockwave Medical announced that the company has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, which is currently the subject of an Investigational Device Exemption study called DISRUPT CAD III. The Shockwave C2 IVL Catheter is a proprietary tool designed to fracture problematic calcium using sonic pressure waves in order to facilitate stent delivery, deployment and optimal expansion, thereby improving blood flow to the heart muscle. DISRUPT CAD III is a prospective, non-randomized, multicenter global IDE study to demonstrate the safety and effectiveness of the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter in de novo, calcified, stenotic, coronary arteries prior to stenting. The study is approved to enroll 442 patients at 50 centers in the United States and Europe, and is led by co-principal investigators Drs. Dean Kereiakes and Jonathan Hill. As reported in the company's second quarter earnings call, the study had enrolled 108 patients as of June 30, 2019. Shockwave C2 Coronary IVL catheters are commercially available for the treatment of de novo coronary artery disease in Europe and select other geographies; they are limited to investigational use in the United States.

08:30 EDT BioLife Solutions announces Mustang Bio adopts CryoStor cell freeze - BioLife Solutions (BLFS) announced that Mustang Bio (MBIO) has adopted BioLife's CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials. After evaluations of various alternatives on the market, Mustang selected BioLife's proprietary CryoStor and evo products to support best biopreservation practices, which focus on maximizing manufacturing yield and quality while reducing distribution-related risks, such as temperature excursions and in-transit shipping damage. The evo cold chain system was added to BioLife's product portfolio via the recently announced acquisition of SAVSU Technologies.

08:29 EDT Zai Lab to initiate ATTACK Phase 3 study of sulbactam-durlobactam in China

08:27 EDT Zai Lab sees potential CTA approval to initiate combination study of brivanib - The company announced anticipated upcoming milestones for brivanib: Potential CTA approval to initiate a combination study of brivanib and a checkpoint inhibitor in the treatment of second-line hepatocellular cancer.

08:23 EDT Zai Lab to initiate bridging tiral of margetuximab in China - The company announced anticipated upcoming milestones for Margetuximab: Initiate bridging trial of heavily pretreated HER2-positive metastatic breast cancer patients in China. MacroGenics to present the results from a pre-specified interim overall survival analysis and submit a Biologics License Application to the U.S. FDA in the fourth quarter of 2019; Potential China CTA approval for the planned global gastric cancer and join MacroGenics to initiate the global registrational trial in combination with checkpoint inhibitor molecules, including INCMGA 0012 and MGD013, for patients with gastric or gastroesophageal junction cancer in 2019.

08:20 EDT Tabula Rasa HealthCare expands services to PACE in Louisiana - Tabula Rasa HealthCare has been selected by PACE of Greater New Orleans to provide medication risk mitigation and comprehensive pharmacy services for the second PACE program in Louisiana. Services will began September 1, 2019. PACE GNO services are provided for PACE participants at its historic Adult Day Health and Activities Centers in the Bywater neighborhood of New Orleans and on the Westbank in Marrero. With the expanded service area, qualified seniors in parts of Jefferson, Orleans, St. Bernard and Plaquemines parishes can benefit from PACE GNO's comprehensive healthcare program and services.

08:16 EDT SWK Holdings expands board, files for uplisting to Nasdaq - SWK Holdings announced that the company has submitted its formal application to list its common shares on Nasdaq. Concurrently, SWK announced the appointment of Winston Black, CEO of SWK, and Aaron Fletcher to its board of directors. The appointments bring the total number of directors to six, of which three satisfy the independence requirements for service on the company's audit committee, including Fletcher.

08:14 EDT Kaleido Biosciences presents data from clinical study of KB195 - Kaleido Biosciences announced data from a clinical study of KB195 in patients with urea cycle disorders are being featured in a poster presentation during the Society for the Study of Inborn Errors of Metabolism Annual Symposium. Data presented at SSIEM are from an open-label, single-arm, clinical study to evaluate the safety, tolerability and effect of KB195 on measures of nitrogen metabolism in patients with well-controlled UCD. The study was conducted at a single center and enrolled four patients who received KB195 orally for 21 days, while continuing their standard of care. In the study, no clinically significant safety signals were observed with KB195 and there were no serious treatment-emergent adverse events. KB195 was generally well tolerated based on measures that included the Gastrointestinal Tolerability Questionnaire, and the Bristol Stool Scale. Patients were well-controlled on their standard of care at study entry, and plasma ammonia levels were within the normal range at baseline and remained normal throughout the study. A lactose-15N-ureide tracer was used to evaluate changes in nitrogen metabolism in the gut. A reduction of this tracer in the urine and an increase of the tracer in the stool are consistent with a reduction in net ammonia production by the gut microbiome. While the study wasn't designed to demonstrate a significant effect on this biomarker of ammonia production, in evaluable patients, KB195 was associated with a general decrease in urinary 15N excretion and an increase in stool 15N excretion, suggestive of KB195 activity in reducing nitrogen metabolism. A global, multi-center, open-label, single arm Phase 2 clinical trial of KB195 is being conducted under an Investigational New Drug application in the U.S. and approved Clinical Trial Application in other countries. It is designed to evaluate the efficacy and safety of KB195 in UCD patients with elevated ammonia levels on standard of care. Patients enrolled in UNLOCKED will receive KB195 administered orally for eight weeks in addition to their standard of care, which includes dietary protein restriction and may include treatment with a nitrogen binding therapy.

08:12 EDT Jason Industries adopts shareholder rights agreement - Jason Industries announced that its board authorized the adoption of a stockholder rights agreement with an eighteen month term. The main purpose of the Rights Agreement is to protect the company's credit agreement from default which could occur if a person or group acquired a significant ownership of the company's outstanding common stock triggering a change in control. A change in control under the credit agreement occurs when a person or group acquires a 35% direct or indirect equity voting power in Jason Partners Holdings Inc. The Rights Agreement also protects the interest and investment of the company's stockholders. The Rights Agreement is intended to protect stockholders from coercive or otherwise unfair takeover tactics. In general terms, it works by imposing a significant penalty upon any person or group which acquires 30% or more of Jason's outstanding common stock without the approval of the board. The Rights Agreement should not interfere with any merger or other business combination approved by Jason's board. Pursuant to the Rights Agreement, the company will issue one preferred share purchase right for each outstanding share of the company's common stock to stockholders of record on the close of business on September 6. Initially, these rights will not be exercisable and will trade with the shares of the company's common stock. Under the Rights Agreement, the rights will generally become exercisable only if a person or group acquires beneficial ownership of 30% or more of the outstanding shares of the company's common stock without first obtaining approval from the board, or announces a tender or exchange offer that would result in beneficial ownership of 30% or more of the company's outstanding common stock. In such situation, each holder of a right will generally be entitled to purchase one one-thousandth of a share of a series of junior preferred stock, for $5, subject to adjustment. Unless earlier redeemed, terminated or exchanged pursuant to the terms of the Rights Agreement, the rights will expire at the close of business on March 1, 2021. If a stockholder or group beneficially owns 30 percent or more of the company's outstanding common stock at the time of the announcement of the Rights Agreement, then that stockholder's existing ownership percentage will be grandfathered, although, with certain exceptions, the rights will become exercisable if at any time after the announcement of the Rights Agreement such stockholder increases its ownership of the company's common stock by 0.001 percent or more.

08:12 EDT ProPetro Holding discloses resignation of General Counsel - In a regulatory filing on August 30, ProPetro Holding disclosed that Mark Howell informed the board of directors of the company of his intent to resign from his position as the General Counsel and Corporate Secretary of the Company, effective September 29. In connection with his resignation, on August 30, the company and Howell entered into a separation and general release agreement pursuant to which, among other things, the parties acknowledged the termination of Howell's employment with the company as of the separation date and executed a mutual release of claims, the company stated.

08:11 EDT Fate Therapeutics announces FDA clearance of IND application for FT596 - Fate Therapeutic announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for FT596, the Company's first off-the-shelf chimeric antigen receptor natural killer cell cancer immunotherapy which targets multiple tumor-associated antigens. FT596 is derived from a clonal master induced pluripotent stem cell line engineered with three functional modalities designed to optimize anti-tumor activity: a proprietary CAR targeting B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 Fc receptor; and an interleukin-15 receptor fusion. The Company plans to initiate clinical investigation of FT596 as a monotherapy and in combination with CD20-directed monoclonal antibodies for the treatment of B-cell lymphoma and chronic lymphocytic leukemia. FT596, which is the first cellular immunotherapy engineered with three active anti-tumor components cleared for clinical investigation by the FDA, is uniquely designed to overcome CD19 antigen escape. In addition to a proprietary CAR targeting CD19, FT596 expresses a novel hnCD16 Fc receptor that has been modified to augment antibody-dependent cellular cytotoxicity, enabling coincident targeting of CD19 and additional antigens such as CD20. FT596 also expresses IL-15RF, a potent cytokine complex that promotes survival, proliferation and trans-activation of NK cells and CD8 T cells without the need for systemic cytokine support. Together, these features of FT596 are intended to maximize potency and minimize toxicity in treated patients. FT596 is the third off-the-shelf, iPSC-derived NK cell product candidate from the Company's proprietary iPSC product platform cleared for clinical investigation by the FDA in less than one year. The Company is conducting first-in-human clinical trials of FT516, an off-the-shelf NK cell cancer immunotherapy engineered to express hnCD16, for the treatment of acute myeloid leukemia and B-cell lymphoma, and FT500, an off-the-shelf NK cell cancer immunotherapy, for the treatment of advanced solid tumors.

08:09 EDT Akebia announces full enrollment of its Phase 3 program for vadadustat - Akebia Therapeutics announced full enrollment of its global Phase 3 program evaluating the safety and efficacy of vadadustat for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, in global Phase 3 development for the treatment of anemia due to CKD in dialysis dependent, or DD,-CKD patients and non-dialysis dependent, or NDD,-CKD patients. The Company's global Phase 3 vadadustat program consists of the INNO2VATE studies which were fully enrolled in April 2019 with 3,923 DD-CKD patients, and the PRO2TECT studies which are now fully enrolled with 3,513 NDD-CKD patients.

08:09 EDT Vertex to acquire Semma Therapeutics for $950M - Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950M in cash. Semma has demonstrated a differentiated approach to treat type 1 diabetes, a serious disease affecting over one million people in the United States alone. Semma has made two major scientific advances: the ability to produce large quantities of functional human pancreatic beta cells that restore insulin secretion and ameliorate hypoglycemia in animal models and a novel device that encapsulates and protects these cells from the immune system, enabling durable implantation without the need for ongoing immunosuppressive therapy.

08:07 EDT Teledyne acquires Micralyne - Teledyne Technologies announced that its subsidiary, Teledyne Digital Imaging, has acquired Micralyne. Based in Edmonton, Alberta, Canada, Micralyne is a privately-owned foundry providing Micro Electro Mechanical Systems or MEMS devices. In particular, Micralyne possesses unique microfluidic technology for biotech applications, as well as capabilities in non-silicon-based MEMS often required for human body compatibility.

08:06 EDT BAE Systems selected by German federal police force - BAE Systems has been selected to provide the German federal police force, Bundespolizei, with three 57mm naval guns for its three new 86m Offshore Patrol Vessels, or OPVs. This contract also includes accompanying fire control systems as well as systems integration support. Work is expected to begin immediately and will be performed at the BAE Systems facility in Karlskoga, Sweden. The first unit is scheduled for delivery in 2020.

08:05 EDT iRobot announces Keith Hartsfield as chief product officer - iRobot (IRBT) announced that Keith Hartsfield will take on the role of chief product officer at the company. Reporting directly to iRobot's chairman and CEO Colin Angle, Hartsfield will oversee the company's physical and digital product offerings, providing strategic direction on innovation and vision, new product development, design, competitiveness and partnerships. This newly created position at iRobot will further the company's focus on developing a product portfolio that delivers a customer experience and contributes to organizational growth. Hartsfield joined iRobot on September 3. Hartsfield most recently served as VP, Z Products at HP Enterprise (HPE).

08:03 EDT Genprex anticipates milestones for next year - Genprex announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex immunogene therapy, to market. For the second half of FY19 the company expects to: establish scalability parameters of new, optimized manufacturing method for lipid nanoparticle delivery system as part of new Genprex research and development program; complete protocol for Oncoprex + immunotherapy clinical trial; prepare and file IND for Oncoprex + immunotherapy clinical trial; and determine clinical site selection, expansion strategy and contract with clinical sites for Oncoprex + erlotinib clinical trial. For the first hald of FY20, the company expects to: complete manufacturing scale-up to support trial site expansion and commercial-scale development; complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion; contract with new clinical trial sites for Oncoprex + immunotherapy clinical trial; begin enrolling patients at new clinical sites for Oncoprex + immunotherapy clinical trial; in addition to the milestone updates.

08:02 EDT Smith-Midland announces expansion of safety barrier rental business - Concrete Safety Systems, Smith-Midland's safety barrier rental division, announces expansion of their J-J Hooks precast concrete rental barrier fleet. Plans, driven by customer demand, will increase the rental inventory to more than 250,000 linear feet over the next 6 months, allowing much greater capacity to handle client needs, both small and large projects, and increase the growth opportunities in this highly profitable part of the business. In addition to rental barrier and installation services, CSS has in the past year expanded its range of accessories to include attenuators, reflectors, delineators and flashers. Alongside increased barrier rental inventory will be the growth of product and service offerings to provide clientele a full-service one-stop option. Furthering this action plan is a contract recently signed to buy more than 100,000 linear feet of J-J Hooks barrier and 75 crash attenuators previously purchased by a Smith-Midland customer for a large road construction project nearing completion.

08:01 EDT Camber Energy says unit near completion of natural gas gathering line - Camber Energy announced that its subsidiary Lineal Industries is nearing completion of a natural gas line that transports treated waste methane from a solid waste landfill into a consumer gas distribution system. Tim Connolly, CEO of Lineal Star Holdings, LLC, Camber's recently acquired parent of Lineal, commented, "We are proud of our role in safely and efficiently completing this unique project, directing waste gas to green gas and other productive consumer uses. When our industry needs a specialty construction team with the depth of experience to plan unusual work and reliably execute that plan, they think of Lineal."

07:57 EDT Crescent Point Energy to sell Uinta Basin asset, Saskatchewan assets for $912M - Crescent Point Energy announced that it has entered into definitive agreements with select parties to sell its Uinta Basin asset in its entirety and certain southeast Saskatchewan conventional assets for total cash consideration of approximately $912M. The transaction includes agreements to sell 27,000 boe/d of upstream assets for approximately 4.7 times cash flow. Net debt is expected to improve to approximately $2.75B at year end, down from $4.4B prior to the changes in senior management in 2018. The transactions strengthen balance sheet and lower pro-forma net debt to adjusted funds flow ratio by approximately 0.4 times. The sale is accretive to debt-adjusted funds flow per share by approximately 11%, while also improving the corporate operating netback by approximately five percent, lowering the capital required to sustain annual production and enhancing the company's financial flexibility. The transaction also increases Crescent Point's ability to continue executing its share repurchase program, with approximately $100M of incremental share repurchases budgeted for the remainder of 2019, based on guidance at current strip prices.

07:56 EDT Ardelyx trading halted, news pending

07:54 EDT MacroGenics, Zai Lab to initiate registrational trial of margetuximab in 2019 - In January 2019, MacroGenics (MGNX) presented updated clinical data from a combination study of margetuximab plus pembrolizumab in gastric cancer at the 2019 ASCO Gastrointestinal Cancers Symposium. Based on these positive data, MacroGenics and Zai Lab (ZLAB) plan to initiate a global registrational clinical trial of margetuximab in combination with checkpoint inhibitor molecules, including INCMGA0012 and MGD013 in first line patients with HER2-positive gastric or gastroesophageal junction cancer in 2019.

07:49 EDT Enterprise Products announces officer promotions - Enterprise Products announced the following promotions and new officers, effective immediately: Graham Bacon was elected Executive Vice President and COO. Bacon has been with the company for 28 years. Brent Secrest has been elected Executive Vice President and Chief Commercial Officer. In his 16 years with Enterprise, Secrest has held various leadership positions and most recently served as Senior Vice President, Commercial.

07:46 EDT Gilat Satellite awarded LTE satellite backhaul project from NTT Docomo - Gilat Satellite announced that NTT Docomo awarded Gilat a project for LTE satellite backhaul, to expand its LTE footprint. Gilat in partnership with SKY Perfect JSAT will provide NTT Docomo a solution for rural coverage extension, while ensuring coverage even in challenging weather conditions. NTT Docomo is engaged in a project to extend LTE service to islands and other hard to reach regions to provide a user experience to their customer base throughout Japan. Gilat's satellite backhaul operated by JSAT's JCSAT-4B satellite will enable this Docomo service in selected areas of Japan.

07:38 EDT Pieris Pharmaceuticals appoints Kaufmann as CSO, says CFO Reine to depart - Pieris Pharmaceuticals (PIRS) announced the appointment of Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer and the departure of Allan Reine, M.D., Senior Vice President and CFO. Kaufmann will be responsible for the company's drug discovery, protein engineering and biomanufacturing activities, while overseeing alliance management and serving as site head for its German R&D facility. Prior to joining Pieris, Dr. Kaufmann spent five years at Sanofi (SNY), where he held several executive positions in Industrial Affairs and R&D. Additionally, Dr. Reine will be stepping down from the company later this month to pursue another business opportunity. Dr. Reine will continue to advise the company until the end of the year, at which time Pieris intends to initiate a search to identify a new CFO. Upon Dr. Reine's resignation, Tom Bures, Pieris' Vice President of Finance will serve as the company's Treasurer and Principal Financial and Accounting Officer.

07:38 EDT Standard Lithium completes mobilisation of Phase 1, 2 of Demonstration Plant - Standard Lithium announced that the mobilisation of Phases 1 & 2 of the Company's direct lithium extraction Demonstration Plant has been successfully completed, and that the modules have been secured and are in the process of being installed at the project location at Lanxess' South Plant facility in southern Arkansas. Standard Lithium's Project Team is currently connecting the modules together, installing the site office and control room and beginning to make utility connections. Work at the project location at Lanxess' South Plant facility in southern Arkansas continues to be on-schedule, and installation and utility connection works will continue throughout September, until the final shipment of modules, scheduled for late September/early October.

07:35 EDT Macau reports August casino revenue down 8.6% to 24.26B patacas - Macau's gaming bureau reported August gross revenue from games of fortune in the region decreased 8.6% year-over-year to 24.262B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO).

07:35 EDT Medipharm Labs Australia appoints Andrew Cormack as head of production - MediPharm Labs Australia announced four senior leadership appointments. Andrew Cormack, Head of Production comes from GMP pharmaceutical, nutraceutical and food companies; Rebecca Bond, Financial Controller, an Australia and New Zealand Chartered Accountant brings experience from prior roles working as a pharmaceutical Financial Analyst, Controller and CFO for a research-led conservation organization; Kate Larson, Senior Regulatory Affairs Advisor, is an expert in international pharmaceutical and nutrition industries' regulatory compliance and James Lee, Senior Project Manager brings 15 years of experience in multiple, highly regulated GMP pharmaceutical manufacturing and commercial industries. MediPharm Labs Australia is expected to serve as part of MediPharm Labs' global supply chain platform and a springboard to serving the Asia-Pacific region. It also represents a business model that MediPharm Labs can use for future expansion in other regions of the world.

07:32 EDT Alnylam presented results from Apollo Phase 3 study of Onpattro - Alnylam Pharmaceuticals shared new findings at the Second European Meeting of ATTR Amyloidosis, or EU-ATTR, for Doctors and Patients, being held September 2-3, in Berlin, Germany. The Company and collaborators presented results from a proteome-wide biomarker analysis of samples from the APOLLO Phase 3 study of ONPATTRO, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR, or hATTR, amyloidosis in adults. In addition, results were presented from an analysis of the UK Biobank - a prospective cohort study with genetic, physical, and health data on approximately 500,000 individuals across the United Kingdom - on clinical outcomes and medical history of individuals with the non-pathogenic transthyretin, or TTR, "stabilizing" T119M variant.

07:31 EDT Kura Oncology announces results from Phase 2 trial of tipifarnib - Kura Oncology announced topline results from an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory urothelial carcinomas that carry HRAS mutations. The ongoing, single-agent, single-arm trial is designed to enroll at least 18 patients, with a primary endpoint of progression-free survival rate at 6 months. Secondary endpoints include objective response rate, duration of response and safety. The trial is being conducted at the Samsung Medical Center in Korea. To date, more than 200 patients with relapsed or refractory urothelial carcinoma have been screened for the presence of tumor HRAS mutations. A total of 15 patients were identified to carry tumors with HRAS mutations. Two patients withdrew from the trial prior to their first response assessment. Of the 13 evaluable patients, five experienced confirmed objective responses, according to RECIST 1.1 criteria, for an overall response rate of 38%. Notably, four patients have experienced PFS of greater than 6 months. According to the trial protocol, the primary endpoint is met when at least four patients achieve PFS at 6 months. All patients joined the trial upon progression from at least one prior systemic chemotherapy cycle, with a median of one prior therapy. Tipifarnib has been generally well-tolerated in the trial; adverse events observed are consistent with the known safety profile of tipifarnib. Further analyses of the trial are ongoing, and detailed data are expected to be presented at a future medical meeting.

07:29 EDT The Green Organic Dutchman receives Health Canada approval for new facility - The Green Organic Dutchman, or TGOD, announced that it has obtained approval from Health Canada, under the Cannabis Regulations, to expand operations into its new hybrid greenhouse located in Hamilton, Ontario. The 123,000 square foot facility will serve to increase TGOD's premium organic cannabis production as it expands its sales in Canada. From its climate control systems and water recapture systems to LED lighting, it combines technologies with natural elements such as living soil and natural sunlight. This organic growing facility has a better environmental footprint and lower waste than traditional large-scale cannabis growing. The new facility is the third phase of TGOD's Hamilton site, measuring 166,000 square feet with an annual production capacity of 17,500 kgs of organic cannabis. In line with its commitment to sustainability, TGOD aims to have the building LEED certified.

07:26 EDT CVS Health to expand focus on helping people quit smoking - CVS Health announced it is expanding its focus on helping people quit smoking. Be The First, the five-year, $50M dollar initiative by the company and the CVS Health Foundation to help create the first tobacco-free generation, is tackling the growing challenge of youth vaping with additional investments and new partners, like Discovery Education and the National Medical Association. The company is also bringing its smoking cessation expertise to areas across its businesses, with an expanded focus in 2020 on increasing effective smoking cessation approaches in Medicaid plans, including in Aetna Better Health managed Medicaid plans and together with CVS Caremark clients interested in creating or expanding smoking cession efforts for their Medicaid members. Also, the Aetna Foundation is pledging an additional $2M to provide educational materials and tools to prevent smoking and vaping to thousands of clinicians who are part of such organizations as the American Academy of Pediatrics, the National Medical Association, the National Hispanic Medical Association and the National Association of School Nurses. This funding builds on a $10M commitment Be The First made earlier this year to combat vaping. Through that effort, the CVS Health Foundation, with partners like Discovery Education and the CATCH Global Foundation, is creating an educational curriculum on the dangers of vaping that will be made available to every school district in the U.S., with additional resources being made available to parents at no cost. These anti-vaping initiatives strengthen the accomplishments of the Be The First program to date, including reaching nearly 13M young people, helping more than 200 colleges and universities in their efforts to go tobacco-free, and funding the first-ever vaping cessation program in partnership with the Truth Initiative. As the company looks to 2020, it plans to expand its tobacco-cessation efforts in the Medicaid program, where smoking rates are considerably higher than among all adults. According to the U.S. Centers for Disease Control and Prevention, 25.3% of Medicaid enrollees smoke, compared to 11.8 % of people enrolled in private insurance.

07:22 EDT GNC Holdings partners with Banco De Franquias for Brazil expansion - GNC Holdings announced its partnership with BFG Brasil Comercial de Vitaminas to help expand the company's presence in Brazil. Specializing in the operation and management of major retail brands in Brazil, the partnership will allow GNC to grow its franchise presence outside the United States and reach more consumers in Latin America. The management organization backing BFG Brasil is Banco de Franquias, which also includes the entrepreneurs operating GNC in Argentina and Uruguay.

07:19 EDT Ansys to collaborate with Edge Case Research on autonomous vehicles - Ansys announced it is collaborating with Edge Case Research to engineer the next generation of autonomous vehicles, or AV, with hazard detection capabilities. Through a new OEM agreement, Edge Case Research integrates its AV artificial intelligence, or AI, perception stress testing and risk analysis system, Hologram, within Ansys' AV simulation solution. Through this collaboration, Edge Case Research will integrate Hologram with Ansys' AV open simulation solution. This end-to-end capability analyzes AV algorithms to detect edge cases to advance the development of and help to validate perception algorithms in advanced AV systems. Hologram can be scaled to other industries such as aerospace and defense, mining, agriculture, industrial robotics and any other domain that relies on AI-based vision and perception software.

07:16 EDT Broadridge acquires Financial Database Services - Broadridge announced that it has acquired Financial Database Services, a provider of compensation management, compliance and advisor onboarding solutions for the wealth management industry. The acquisition expands Broadridge's current advisor compensation management capabilities. Financial Database Services, the developer of the CAESAR suite of products, provides a modular suite of compensation and compliance tools to the marketplace, including advisor onboarding and analytics solutions. Terms of the deal were not disclosed.

07:13 EDT BioLineRx completes dose-escalation of Phase 1/2a clinical study for AGI-134 - BioLineRx announced that it has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens. AGI-134 was found to be safe and well tolerated, with no serious drug-related adverse events or dose-limiting toxicities reported. The maximal tolerated dose was not reached and the recommended dose for part 2 of the study was determined. The ongoing Phase 1/2a study is a multicenter, open-label study expected to take place at approximately 15 sites in the US, UK and Israel. The objectives of the study are to evaluate the safety and tolerability of AGI-134 at the recommended dose in multiple solid tumor types, to evaluate a wide array of biomarkers, and to validate AGI-134's mechanism of action. Furthermore, efficacy will be assessed by clinical and pharmacodynamic parameters. The dose-expansion part 2 of the study is expected to commence shortly.

07:12 EDT Rexford Industrial acquires five properties for $110.3M, sells two for $12.8M - Rexford Industrial Realty announced the acquisition of five industrial properties for a total of $110.3M and the disposition of two properties for $12.8M. The acquisitions were funded using cash-on-hand as well as the reinvestment of disposition proceeds. The company also completed two disposition transactions, comprising the following: a 6,562 SF industrial condo unit located at 939 Poinsettia Avenue in Vista, within the San Diego - North County submarket, sold for $1.3M, or $193 per square foot; a 62,395 SF multi-tenant complex located at 2350-2384 Orangethorpe Avenue and 1631 Placentia Avenue, in Fullerton within the Orange County - North submarket, sold for $11.5M, or $185 per square foot. Proceeds from both dispositions were recycled in tax deferred 1031 exchanges to fund portions of the Company's acquisitions.

07:10 EDT RioCan REIT closes acquisition of 50% interest in Yonge Sheppard Center - RioCan Real Estate Investment Trust announced that it has completed the acquisition of KingSett Capital's Canadian Real Estate Income Fund non-managing, 50% co-ownership interest in Yonge Sheppard Centre for $357.6M, based on KingSett's share of costs as of August 30, 2019, net of certain working capital adjustments. As part of the transaction, KingSett took a material equity position in RioCan through an investment of $100M in RioCan units with a one-year lock-up agreement commencing August 30, 2019. This transaction brings RioCan's ownership of the nearly one million square foot, urban mixed-use property at the intersection of Yonge Street and Sheppard Avenue in Toronto, Ontario to 100%. The fully revitalized property serves as the hub of this important and rapidly growing Toronto neighbourhood. As part of the transaction, RioCan assumed KingSett's share of the existing property debt and has issued $100M of RioCan units out of treasury to KingSett at the 5-day volume weighted average unit trading price of $26.25 as of June 5, 2019, the date the firm agreement was entered into by the parties. Subsequent to the transaction closing, RioCan effectively used a portion of the net proceeds from its recently announced $500.0 million Series AB debenture issuance, which carries a coupon rate of 2.576% per annum, to repay without prepayment penalty $265.6 million of existing property debt on Yonge Sheppard Centre. The existing property debt was a floating rate loan which carried an interest rate of 3.15% based on prevailing rates, resulting in further interest savings for RioCan. The acquisition of the remaining interest in this important asset accelerates RioCan's major market and Greater Toronto Area presence, expands our RioCan Living portfolio and provides significant income and value growth potential.

07:08 EDT Osisko Bermuda enhances Silver Purchase agreement with Mantos Copper - Osisko Gold Royalties announced that its wholly-owned subsidiary, Osisko Bermuda Limited has entered into a definitive agreement with Mantos Copper to enhance its existing Silver Purchase Agreement with respect to 100% of the silver produced from the Mantos Blancos copper mine located in Chile. The Stream Amendment Transaction is part of a comprehensive $250M financing package entered into by Mantos Copper to expand the Project's sulphide concentrator plant. Under the terms of the Stream Amendment Transaction, OBL has agreed to provide an additional deposit of $25M to Mantos Copper in exchange for certain amendments to the existing Silver Purchase Agreement, including: reduction of the ongoing transfer price payment per ounce from 25% to 8% of the spot silver price on the date of delivery; and increase in the tail stream from 30% to 40% of payable silver after 19.3 million ounces of refined silver have been delivered. Mantos Copper's right to buy back 50% of the silver stream in September 2019 or 2020 has also been terminated. Concurrent with the Stream Amendment Transaction, Mantos Copper has entered into definitive agreements for a $150M offtake facility from Complejo Metalurgico Altonorte S.A. and a $50M copper royalty agreement with Anglo Pacific Group PLC. Together with US$25 million of committed equity funding from Mantos Copper's majority shareholder, Orion Mine Finance, the combined proceeds will fund the $219M capital cost of the Expansion and associated working capital requirements. The Expansion is expected to increase the throughput of the Project's sulphide concentrator plant from 4.3 Mtpa to 7.3 Mtpa by mid-2021 and extend the life of the Project to 2035. Upon completion of the Expansion, the Project is expected to produce an average of 52 Kt of copper per annum at an average C1 cash cost of $1.87 per pound during the first 10 years, with both production upside and mine life extension potential. Life-of-mine deliveries of refined silver to OBL under the amended Silver Purchase Agreement are expected to total over 13.9M ounces, with annual deliveries during the first five years following commissioning of the Expansion expected to average approximately 1.2M ounces of refined silver per year.

07:02 EDT uniQure achieves planned enrollment in HOPE-B trial of AMT-061 - uniQure announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. Due to the high level of interest in the study from both patients and study investigators, uniQure expects to over-enroll up to six additional patients before the end of September. Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines regulatory initiative by the European Medicines Agency. The pivotal Phase III HOPE-B study builds on the success of the interim 36-week results of the Company's ongoing Phase IIb study of etranacogene dezaparvovec, which demonstrated that a single administration of the investigational gene therapy resulted in sustained increases in Factor IX levels up to 54% of normal, and a mean FIX level of 45% of normal. During that time, no patient reported any bleeding events or required any infusion of FIX replacement therapy for bleeds or experienced any material loss of FIX activity. Additionally, an ongoing Phase I/II study of AMT-060, the Company's first-generation gene therapy for the treatment of hemophilia B, demonstrated that all 10 patients continue to show sustained and stable increases in FIX activity and long-term clinical benefits at up to 3.5 years of observation.

06:54 EDT Ares Management enters renewable power purchase agreement with Facebook - Ares Management's (ARES) Infrastructure and Power strategy and Apex Clean Energy announced that Aviator Wind East, an approximately 200 MW portion of the 525 MW Aviator Wind project located in Coke County, Texas, has executed a renewable power purchase agreement with Facebook (FB). Aviator Wind will be the largest single-phase wind project in ERCOT and the largest single-phase, single-site wind project in the United States. Aviator Wind East, which will be operational in 2020, will help support Facebook's operations in the region. The contract will help the tech company reach its goal to reduce its greenhouse gas emissions by 75% and support 100% of its operations with renewable energy in 2020. Facebook's portion of the Aviator Wind project will be 199.76 MW. Aviator Wind is Ares Infrastructure and Power's eleventh wind investment, which collectively represent 4 GW of power generation, and is a continuation of Apex's partnership with Ares Infrastructure and Power. Apex Clean Energy will provide both construction and asset management services for the project. An additional unnamed corporate power purchase agreement for the majority of the balance of Aviator Wind, known as Aviator Wind West, will be announced at a later date.

06:51 EDT Babcock & Wilcox enters strategic collaboration with JZHC - Babcock & Wilcox has signed a strategic collaboration agreement with John Zink Hamworthy Combustion, or JZHC, that pairs JZHC's Coen burners with B&W's water-tube package boilers and allows the companies to market the combined burner and boiler solution to their customers. The agreement combines B&W's package boiler expertise with Coen's ultra-low-NOx emissions burners and combustion experience to provide steam generation solutions to customers in a variety of industries, including refining, petrochemical, pulp and paper, mining, manufacturing, utilities and others. B&W's package boilers are engineered to meet unique capacity, space, fuel, emissions, transportation, installation and other requirements. They offer power with low emissions, low auxiliary power requirements, simple operation, low maintenance and can be tailored for a variety of fuel options, including natural gas.

06:46 EDT Corindus announces publication of results from Telerobotic Intervention Study - Corindus Vascular Robotics announced that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has published the results from the Telerobotic Intervention Study, the world's first percutaneous coronary intervention, PCI, procedures conducted from a remote location outside the catheterization lab using Corindus' CorPath technology platform. The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, discusses five successful patient cases performed by Tejas Patel, Chairman and Chief Interventional Cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India.

06:42 EDT National Oilwell awarded package and design orders by Shimizu - National Oilwell Varco has been awarded equipment package and design orders for one of the world's largest offshore wind turbine installation vessels by Japanese-based Shimizu Corporation. NOV, through its subsidiary GustoMSC, has worked closely with Shimizu on the customized jack-up design which has a total tonnage of 28,000t and is capable of accommodating 130 people. The vessel will also incorporate a proprietary 2500t telescopic leg crane designed specifically for the offshore wind market to provide a unique combination of high elevation hoisting capability for turbine installation and heavy load capability for foundation installation. Japan Marine United shipyard will carry out the construction of the unit. Planning is underway in Japan for a total of 9GW of offshore windfarm generation capacity using a new generation of larger, more economically efficient, ultra-large-scale wind turbines of 9 to 12 MW in size. Delivery of this vessel, which will be the largest and most-capable in the region, is expected in late 2022.

06:39 EDT Emergent BioSolutions awarded $2B contract by U.S. HHS - Emergent BioSolutions announced a contract award by the Office of the Assistant Secretary for Preparedness and Response, or ASPR, in the U.S. Department of Health and Human Services, or HHS, valued at approximately $2B over 10 years for the continued supply of ACAM2000, or Smallpox Vaccine, into the U.S. Strategic National Stockpile, or SNS. The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR. ACAM2000 vaccine is the only vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. This contract for the procurement of ACAM2000 vaccine consists of a one-year base period of performance, valued at approximately $170M, and nine option years. The company expects to deliver into the SNS a majority of the doses under the base year by year end 2019, the effect of which is already included in the company's full year financial forecast, which was recently reaffirmed on August 1. This multiple year contract is intended to support the replacement of the smallpox vaccine stockpile and follows the conclusion of a prior 10-year, $425M contract to establish domestic warm-base manufacturing capabilities and procure smallpox vaccines issued by the U.S. government April 1, 2008.

06:38 EDT EMC Insurance announces ISS recommendation for EMCC acquisition - EMC Insurance announced that independent proxy advisory firm, Institutional Shareholder Services, or ISS, recommends that EMCI shareholders vote for Employers Mutual Casualty Company's, or EMCC, proposed acquisition of all of the shares of EMCI that EMCC does not already own. The EMCI board, based on the unanimous recommendation of its special committee, recommends that EMCI minority shareholders vote for the proposal to approve the transaction, as described in more detail in the definitive proxy statement that was filed with the SEC on August 8. As previously announced, the EMCI special meeting of shareholders to vote on the transaction is scheduled to take place on September 18.

06:35 EDT Zedge appoints Michael Jonas as interim CEO - Zedge announced that Tom Arnoy, Zedge's co-founder and CEO has resigned, effective August 31. Michael Jonas, Chairman of the Board, has been named interim CEO as the Company commences the process of identifying a replacement.

06:20 EDT CNH Industrial to take $250M strategic stake in Nikola - CNH Industrial announced its intention to enter into a strategic and exclusive Heavy-Duty Truck partnership with Nikola, based in Phoenix, Arizona, U.S.A., to accelerate industry transformation towards emission neutrality of Class 8 / Heavy-Duty Trucks in North America and Europe through the adoption of fuel-cell technology. Nikola's zero-emission Heavy Duty Trucks, powered by proprietary hydrogen fuel cell and battery technology, will be the first-to-production. CNH Industrial will take a $250M strategic stake in Nikola as the lead Series D investor, comprising $100M cash and $150M in services, such as product development, manufacturing engineering, and other technical assistance, as well as supply of certain key components to accelerate the production timeline of the Nikola TWO and Nikola TRE. Pre-money valuation was set at $3B. Nikola anticipates raising over $1B in the D round, granting approximately 25% ownership to new investors and business partners, including CNH Industrial.

06:13 EDT Tutor Perini selected as preferred proponent for Miami-Dade County courthouse - Tutor Perini announced that its team has been identified as the Preferred Proponent for the Miami-Dade County New Civil and Probate Courthouse in Miami, Florida. The construction value is in excess of $260M. The project will be executed under a Public-Private Partnership delivery model, which will provide for the design, construction, financing, operations and maintenance of the courthouse under a single contractual agreement. Tutor Perini is the design-build contractor and is teamed on this project with Plenary Group, the developer and financial sponsor; HOK, the architect/designer; and Johnson Controls, Inc., the operations and maintenance partner. The new courthouse facility will provide more than 600,000 square-feet of space and services related to Civil and Probate Divisions of the Eleventh Judicial Circuit of Florida, the Clerk of Courts and other related court partners and agencies. The project will include construction of 46 jury courtrooms and shell space for an additional four jury courtrooms; a parking area with secure parking for 59 vehicles; site development, including necessary utilities and utility improvements to support the facility; hardscape/landscape; and road and traffic control improvements.

06:10 EDT Cidara Therapeutics, Mundipharma enter partnership to develop rezafungin - Cidara Therapeutics and Mundipharma announced that they have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal infections. Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation, for which no new therapies have been approved in over 13 years. The partnership agreement follows Cidara's recent announcement of the successful completion of its STRIVE B Phase 2 trial. Under the terms of the agreement, in exchange for granting Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan, Cidara will receive a $30M upfront payment and Mundipharma will make a $9M equity investment in Cidara. Cidara will also receive an additional $42M in near-term funding to support the global Phase 3 ReSTORE and ReSPECT trials for the treatment and prevention of fungal infections. In addition, Cidara is eligible to receive development, regulatory and commercial milestone payments, representing a total potential transaction value of $568M plus double-digit royalties. Cidara will continue to lead the ongoing global Phase 3 development programs for rezafungin with the support of Mundipharma. The companies may pursue additional indications or formulations of rezafungin.

06:02 EDT Maxar Technologies signs contract renewal with international customer - Maxar Technologies announced that it has signed a delayed contract renewal in its Imagery segment with an International Defense and Intelligence customer, as described in the second quarter 2019 earnings call presentation. The contract renewal encompasses services that Maxar began providing on February 1, and will provide through Jan. 31, 2020.

05:37 EDT CUI Global announces GasPTi orders from U.S. energy producer, transporter - CUI Global wholly-owned Energy subsidiary, Orbital Gas Systems, announced that it has received orders to supply GasPTi systems for deployment across multiple natural gas plants by "one of the largest U.S.-based producers and transporters of energy." These orders, part of a nascent, ongoing roll-out of GasPTi across the customer's extensive natural gas assets, will be utilized to deliver operating and environmental improvements and practically eliminate ongoing costs associated with maintenance and natural gas consumption at certain customer facilities.

05:25 EDT Zealand Pharma, Boehringer Ingelheim initiate Phase 2 development of BI 456906 - Boehringer Ingelheim and Zealand Pharma announce that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand's expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim's expertise in the research and development of novel medicines for cardiometabolic diseases. The decision to advance BI 456906 to Phase 2 clinical testing is based on the safety and tolerability and the favorable weight loss potential in individuals with a BMI up to 40 kg/m2. The Phase 2 trial will be a dose-finding, placebo and active comparator clinical proof of concept trial in patients with obesity and type 2 diabetes.